Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$91.50
neg -0.05
-0.05%
Today's Range: 90.69 - 92.60 | GILD Avg Daily Volume: 11,345,800
Last Update: 08/01/14 - 4:00 PM EDT
Volume: 11,955,397
YTD Performance: 21.90%
Open: $91.00
Previous Close: $91.55
52 Week Range: $55.96 - $94.34
Oustanding Shares: 1,535,682,107
Market Cap: 144,031,624,816
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 15 15 16
Moderate Buy 1 1 2 2
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.36 1.28 1.32 1.30
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 20.08
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
20.08 21.10 28.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.64% 49.10% 332.25%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 121.60 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.40 $1.91 $6.21 $8.47
Number of Analysts 3 3 4 4
High Estimate $1.64 $2.66 $7.76 $9.88
Low Estimate $1.22 $1.52 $5.51 $7.31
Prior Year $0.50 $0.52 $1.92 $6.21
Growth Rate (Year over Year) 180.67% 267.31% 223.18% 36.46%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Aug 1, 2014 | 2:38 PM EDT
We'll see.
By

Bret Jensen

 | Aug 1, 2014 | 9:13 AM EDT
Apple and Gilead Sciences are on it.
By

Jim Cramer

 | Jul 30, 2014 | 11:11 AM EDT

Where what the Fed does allegedly determines everything.

By

Jim Cramer

 | Jul 29, 2014 | 4:21 PM EDT

Something worrisome has me fretting more than I have in a while.

By

Bret Jensen

 | Jul 25, 2014 | 10:00 AM EDT

This week's earnings gave me a little more confidence about market valuation.

bullishGilead estimates, target increased at Leerink

Jul 24, 2014 | 7:56 AM EDT

GILD estimates were raised through 2015, Leerink Swann said. Company boosted its guidance, given higher Sovaldi sales. Outperform rating and new $109 price target. 

By

Jim Cramer

 | Jul 23, 2014 | 1:54 PM EDT

McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

By

Gary Dvorchak

 | Jul 21, 2014 | 1:30 PM EDT

Behold, my long list of fresh ideas this earnings season.

By

Bret Jensen

 | Jul 21, 2014 | 10:30 AM EDT

Of the more than 100 companies reporting earnings this week, here are some I will be watching.

By

Gary Dvorchak

 | Jul 18, 2014 | 8:30 AM EDT

I will book my 50% gain and look for the next good idea.

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Bef...
Last year saw the MC NYSE oscillator hit -300 on about five occasions, and each time a mas...
If you are in the NYC area, Bob Lang and I will be in town this Monday and Tuesday night. ...
There are no signals in IWM....Still watching zone 2 in WYNN for a potential entry. The up...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.